Double-blind study shows ivermectin reduces disease’s duration and infectiousness • FDA and WHO caution against its use

Ivermectin, a drug used to fight parasites in third-world countries, could help reduce the length of infection for people who contract coronavirus for less than a $1 a day, according to recent research by Sheba Medical Center in Tel Hashomer.
Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, conducted a randomized, controlled, double-blinded trial from May 15, 2020, through the end of January 2021 to evaluate the effectiveness of ivermectin in reducing viral shedding among nonhospitalized patients with mild to moderate COVID-19.
Ivermectin has been approved by the US Food and Drug Administration since 1987. The drug’s discoverers were awarded the 2015 Nobel Prize in medicine for its treatment of onchocerciasis, a disease caused by infection with a parasitic roundworm.
Over the years, it has been used for other indications, including scabies and head lice. Moreover, in the last decade, several clinical studies have started to show its antiviral activity against viruses ranging from HIV and the flu to Zika and West Nile.  (See link for article)
The study found in MedRxiv, a health-research sharing site, has not yet been peer reviewed.  The study found:
  • Approx. 72% of the Ivermectin group tested negative and 13% were infectious after day six
  • 50% of the placebo group tested positive and 50%, almost 4 times as many, were infectious after day six
  • 5 patients were referred to hospitals, 4 of them were in the placebo group
  • One hospitalized patient complained of shortness of breath, continued on ivermectin and was sent back to the hotel a DAY later in good condition
“Our study shows first and foremost that ivermectin has antiviral activity,” Schwartz said. “It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact.”
The study author points out that while this study did not address ivermectin as a prophylactic, or address hospitalization reduction, other studies have shown such evidence.
Other studies have shown:
  • 27 studies demonstrate ivermectin’s ability to prevent COVID
  • a recent review found ivermectin reduced death by 75%

Please see:  


Interestingly, ivermectin is on the WHO’s list of essential medicines yet an Israeli professor states there’s significant risks with it and that ‘caution should be used on a virus that the vast majority of the public will recover from without treatment.’  He didn’t bother to mention anything about fast-tracked experimental “vaccines” that thousands have been maimed and killed from and that experts are warning against.
To date the WHO is not supporting any trials to determine ivermectin’s viability.
Researchers in other places worldwide began looking into the drug at around the same time. But when they started to see positive results, no one wanted to publish them, Schwartz said.
“There is a lot of opposition,” he said. “We tried to publish it, and it was kicked away by three journals. No one even wanted to hear about it. You have to ask how come when the world is suffering.”
This drug will not bring any big economic profits,” and so Big Pharma doesn’t want to deal with it, he said.
The article points out that some of the loudest opposition has come from Merck, the manufacturer of ivermectin since the 80’s.  Merck was peddling COVID vaccines until it was discovered “the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.”  Now it’s peddling molnupiravir, which raked in 1.2 BILLION from a deal with the U.S. government.  It is currently in a phase 3 clinical trail.  So why make pennies when you can make BILLIONS?
For more:
%d bloggers like this: